Literature DB >> 27881488

An Opsonic Phagocytosis Assay for Plasmodium falciparum Sporozoites.

Ryan W J Steel1, Brandon K Sack1, Moriya Tsuji2, Mary Jane L Navarro1, Will Betz1, Matt E Fishbaugher1, Erika L Flannery1, Stefan H I Kappe3,4.   

Abstract

Plasmodium falciparum malaria remains the deadliest parasitic disease worldwide. Vaccines targeting the preerythrocytic sporozoite and liver stages have the potential to entirely prevent blood-stage infection and disease, as well as onward transmission. Sporozoite surface and secreted proteins are leading candidates for inclusion in a preerythrocytic stage-specific, antibody-based vaccine. Preclinical functional assays to identify humoral correlates of protection in vitro and to validate novel sporozoite protein targets for inclusion in multisubunit vaccines currently do not consider the interaction of sporozoite-targeting antibodies with other components of the immune system. Here, we describe the development of a simple flow cytometric assay to quantitatively assess the ability of antibodies directed against P. falciparum sporozoites to facilitate their phagocytosis. We demonstrate that this sporozoite opsonic phagocytosis assay (SOPA) is compatible with both monoclonal antibodies and human immune serum and can be performed using cryopreserved P. falciparum sporozoites. This simple, accessible assay will aid with the assessment of antibody responses to vaccination with Plasmodium antigens and their interaction with phagocytic cells of the immune system.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Plasmodium falciparum; antibodies; assay development; malaria; opsonization; phagocytosis; sporozoite; vaccines

Mesh:

Substances:

Year:  2017        PMID: 27881488      PMCID: PMC5299119          DOI: 10.1128/CVI.00445-16

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  33 in total

1.  Migration of Plasmodium sporozoites through cells before infection.

Authors:  M M Mota; G Pradel; J P Vanderberg; J C Hafalla; U Frevert; R S Nussenzweig; V Nussenzweig; A Rodríguez
Journal:  Science       Date:  2001-01-05       Impact factor: 47.728

Review 2.  An expanding toolkit for preclinical pre-erythrocytic malaria vaccine development: bridging traditional mouse malaria models and human trials.

Authors:  Ryan Wj Steel; Stefan Hi Kappe; Brandon K Sack
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

3.  Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.

Authors:  Andrew S Ishizuka; Kirsten E Lyke; Adam DeZure; Andrea A Berry; Thomas L Richie; Floreliz H Mendoza; Mary E Enama; Ingelise J Gordon; Lee-Jah Chang; Uzma N Sarwar; Kathryn L Zephir; LaSonji A Holman; Eric R James; Peter F Billingsley; Anusha Gunasekera; Sumana Chakravarty; Anita Manoj; MingLin Li; Adam J Ruben; Tao Li; Abraham G Eappen; Richard E Stafford; Natasha K C; Tooba Murshedkar; Hope DeCederfelt; Sarah H Plummer; Cynthia S Hendel; Laura Novik; Pamela J M Costner; Jamie G Saunders; Matthew B Laurens; Christopher V Plowe; Barbara Flynn; William R Whalen; J P Todd; Jay Noor; Srinivas Rao; Kailan Sierra-Davidson; Geoffrey M Lynn; Judith E Epstein; Margaret A Kemp; Gary A Fahle; Sebastian A Mikolajczak; Matthew Fishbaugher; Brandon K Sack; Stefan H I Kappe; Silas A Davidson; Lindsey S Garver; Niklas K Björkström; Martha C Nason; Barney S Graham; Mario Roederer; B Kim Lee Sim; Stephen L Hoffman; Julie E Ledgerwood; Robert A Seder
Journal:  Nat Med       Date:  2016-05-09       Impact factor: 53.440

4.  Interactions of Plasmodium berghei sporozoites and murine Kupffer cells in vitro.

Authors:  M C Seguin; W R Ballou; C A Nacy
Journal:  J Immunol       Date:  1989-09-01       Impact factor: 5.422

5.  Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes.

Authors:  Jerome P Vanderberg; Ute Frevert
Journal:  Int J Parasitol       Date:  2004-08       Impact factor: 3.981

Review 6.  The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review.

Authors:  Judith E Epstein; Thomas L Richie
Journal:  Curr Opin Infect Dis       Date:  2013-10       Impact factor: 4.915

7.  Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.

Authors:  Danny W Wilson; Freya J I Fowkes; Paul R Gilson; Salenna R Elliott; Livingstone Tavul; Pascal Michon; Elija Dabod; Peter M Siba; Ivo Mueller; Brendan S Crabb; James G Beeson
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

8.  Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria.

Authors:  Michelle J Boyle; Linda Reiling; Gaoqian Feng; Christine Langer; Faith H Osier; Harvey Aspeling-Jones; Yik Sheng Cheng; Janine Stubbs; Kevin K A Tetteh; David J Conway; James S McCarthy; Ivo Muller; Kevin Marsh; Robin F Anders; James G Beeson
Journal:  Immunity       Date:  2015-03-17       Impact factor: 31.745

9.  Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria.

Authors:  Faith Ha Osier; Gaoqian Feng; Michelle J Boyle; Christine Langer; Jingling Zhou; Jack S Richards; Fiona J McCallum; Linda Reiling; Anthony Jaworowski; Robin F Anders; Kevin Marsh; James G Beeson
Journal:  BMC Med       Date:  2014-07-01       Impact factor: 8.775

10.  The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection.

Authors:  Michael T White; Philip Bejon; Ally Olotu; Jamie T Griffin; Eleanor M Riley; Kent E Kester; Christian F Ockenhouse; Azra C Ghani
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more
  5 in total

1.  Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria.

Authors:  Fauzia K Musasia; Irene N Nkumama; Roland Frank; Victor Kipkemboi; Martin Schneider; Kennedy Mwai; Dennis O Odera; Micha Rosenkranz; Kristin Fürle; Domitila Kimani; James Tuju; Patricia Njuguna; Mainga Hamaluba; Melissa C Kapulu; Hedda Wardemann; Faith H A Osier
Journal:  Nat Commun       Date:  2022-07-14       Impact factor: 17.694

2.  Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and may enhance protection of anti-CSP monoclonal antibodies.

Authors:  Brandon K Wilder; Vladimir Vigdorovich; Sara Carbonetti; Nana Minkah; Nina Hertoghs; Andrew Raappana; Hayley Cardamone; Brian G Oliver; Olesya Trakhimets; Sudhir Kumar; Nicholas Dambrauskas; Silvia A Arredondo; Nelly Camargo; Annette M Seilie; Sean C Murphy; Stefan H I Kappe; D Noah Sather
Journal:  NPJ Vaccines       Date:  2022-05-26       Impact factor: 9.399

3.  Expanding the Malaria Antibody Toolkit: Development and Characterisation of Plasmodium falciparum RH5, CyRPA, and CSP Recombinant Human Monoclonal Antibodies.

Authors:  Adéla Nacer; Gaily Kivi; Raini Pert; Erkki Juronen; Pavlo Holenya; Eduardo Aliprandini; Rogerio Amino; Olivier Silvie; Doris Quinkert; Yann Le Duff; Matthew Hurley; Ulf Reimer; Andres Tover; Simon J Draper; Sarah Gilbert; Mei Mei Ho; Paul W Bowyer
Journal:  Front Cell Infect Microbiol       Date:  2022-06-16       Impact factor: 6.073

4.  Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children.

Authors:  Liriye Kurtovic; Paul A Agius; Gaoqian Feng; Elizabeth H Aitken; Jahit Sacarlal; Bruce D Wines; P Mark Hogarth; Stephen J Rogerson; Freya J I Fowkes; Carlota Dobaño; James G Beeson
Journal:  BMC Med       Date:  2022-08-25       Impact factor: 11.150

5.  Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein.

Authors:  Lawrence T Wang; Lais S Pereira; Patience K Kiyuka; Arne Schön; Neville K Kisalu; Rachel Vistein; Marlon Dillon; Brian G Bonilla; Alvaro Molina-Cruz; Carolina Barillas-Mury; Joshua Tan; Azza H Idris; Joseph R Francica; Robert A Seder
Journal:  PLoS Pathog       Date:  2021-12-06       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.